BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy - Wikidata - wikimedia - TriplyDB

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

http://www.wikidata.org/entity/Q27650860

about

Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy Therapeutic Approach to Adult Fibrotic Lung Diseases Nintedanib in NSCLC: evidence to date and place in therapy Pharmacological management of IPF Profile of bevacizumab in the treatment of platinum-resistant ovarian cancer: current perspectives New perspectives on management of idiopathic pulmonary fibrosis Idiopathic pulmonary fibrosis: current treatment options and critical appraisal of nintedanib Profile of nintedanib in the treatment of solid tumors: the evidence to date Clinical development of nintedanib for advanced non-small-cell lung cancer Targeting RTK Signaling Pathways in Cancer Nintedanib: evidence for its therapeutic potential in idiopathic pulmonary fibrosis Targeting angiogenesis in squamous non-small cell lung cancer Ovarian cancer standard of care: are there real alternatives?Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib Clinical investigation of receptor and non-receptor tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer Nonsmall cell lung cancer therapy: insight into multitargeted small-molecule growth factor receptor inhibitors The 1.65 Å resolution structure of the complex of AZD4547 with the kinase domain of FGFR1 displays exquisite molecular recognition Design, synthesis and biological evaluation of novel FGFR inhibitors bearing an indazole scaffold Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer.Escaping Antiangiogenic Therapy: Strategies Employed by Cancer Cells Idiopathic Pulmonary Fibrosis: Treatment and Prognosis Angiogenesis Inhibitors for the Treatment of Hepatocellular Carcinoma Precision targeted therapy of ovarian cancer Update on diagnosis and treatment of idiopathic pulmonary fibrosis Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR FGF receptors: cancer biology and therapeutics Current issues in malignant pleural mesothelioma evaluation and management A high-content EMT screen identifies multiple receptor tyrosine kinase inhibitors with activity on TGFβ receptor A place for precision medicine in bladder cancer: targeting the FGFRs.First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value.A phase I, open-label dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin as first-line treatment in patients with advanced non-small-cell lung cancer.Emerging data with antiangiogenic therapies in early and advanced non-small-cell lung cancer.Inhibition of lymphangiogenesis in vitro and in vivo by the multikinase inhibitor nintedanib.A current review of targeted therapeutics for ovarian cancer.Antivascular therapy for epithelial ovarian cancer.The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes Gonad RNA-specific qRT-PCR analyses identify genes with potential functions in schistosome reproduction such as SmFz1 and SmFGFRs.Is fibroblast growth factor receptor 4 a suitable target of cancer therapy?Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription.

P2860

Q26738458-731AAAC9-6884-43BB-992E-11069AF4AD07 Q26741569-FC694C56-9DD1-4B81-A841-CD31AF9C067A Q26745424-1E71200E-EEB8-4575-8C81-B5B4D3936266 Q26748808-D46ED6B5-AB91-48CF-8CD7-0EACF7611CE5 Q26751280-B41A709A-2AD7-4FF9-838B-2DBBF4274A57 Q26765586-10C7D760-BEB1-4EF9-A204-481973778236 Q26771647-2CCCBFA6-B938-412F-BF2A-ADB751E59A81 Q26775134-6B1EE33D-8EF3-431B-BD8C-BC00A4CD2177 Q26775822-E12D84C3-EDAC-4DD7-AE37-F950E26C3B00 Q26781278-E0F59C24-C60C-429B-99FD-3F678AEB0C79 Q26783169-8A2D0BA4-B8CD-42EF-B4DE-4F6359627AFE Q26861341-EDCCB9A7-162A-4199-8BED-8ED7F45C3816 Q26862249-16EC7D1E-6431-4A10-B325-74E58F425A59 Q26995204-7AAA9833-F870-484E-AA6E-2026B0261CC0 Q27024235-7072D576-2047-4864-9DA7-D17F74E962FF Q27693185-2E6E70AC-DA25-4EC5-A05E-46B2CFD2B5E7 Q27698320-CB59BAC6-3CA3-441C-A958-3872B007FD5B Q27701029-17F134B3-9BF4-44DA-AFFD-914CEE753C3A Q27851654-729D5892-03D1-4A50-89F8-E500EE386A58 Q28067753-D79AFC4C-6187-446E-9625-E97C3611090B Q28073641-9A57E596-7128-44B0-883C-884C99E8B6BA Q28075305-743A72A5-1E0A-40BD-87D8-391E30466557 Q28078658-BF1CFDFF-4B8B-4CA7-87F9-6B80B8BA0301 Q28083702-39A07B95-46A5-4D4B-B605-CC5BC0010BA1 Q28085104-3E956F0B-536E-49DE-BAC6-9B0933A17AE0 Q28086993-E6321734-9A03-4528-B3A2-52C3305484C1 Q28291186-378FA4C6-503A-4710-ABEA-03EDFD98C4CC Q28393560-2F8E89FD-5C2A-4021-8CED-25CD4519470A Q28828478-696CBA5C-BE8B-41F1-97B0-42E981CE38EE Q30249143-19BC6CEB-CABD-49B6-BF37-EB6D99169A0B Q31112375-17210A06-0CBA-4552-B5C4-3E1983167E76 Q33399785-7742C3C5-F73D-4E23-9AD9-23DA868BC39E Q33429478-F9FB893A-B6A5-4CAC-9B46-2477A60B5830 Q33563488-71DCE7AC-B1CF-4381-8E18-101AAA885EDB Q33580998-E769F6D9-AE41-47CC-B859-EE74FE9A7EE9 Q33583598-DA4786CC-0135-4AFE-9741-336EE60AFBE3 Q33601748-F0091739-1FD5-4670-AEBE-835D2CAA785C Q33730904-210CB644-6108-478C-804A-69F0FB7E41A3 Q33751398-A653C28E-D075-4E36-B7E3-DDD43FCA09C6 Q33840143-DFDA63EC-6CBF-4D54-89E1-B604705FF130

P2860

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy

http://www.wikidata.org/entity/Q27650860

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@ast

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@en

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@nl

type

label

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@ast

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@en

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@nl

prefLabel

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@ast

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@en

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@nl

P1433

Q27650860-55F59E55-A848-4031-B666-68331ED22275

P1476

Q27650860-84AAAC5B-8BF0-406B-A6CF-29AE9C8AA2D6

P2093

Q27650860-1500D39A-C1AC-45C6-A3F6-5210BD1AB8E1

Q27650860-197F084C-F54F-43D3-8A59-85412411FCD8

Q27650860-1987D53D-AB5A-4B4A-8E3B-72C23932ECF6

Q27650860-1B093EFD-B30C-4055-961D-79D6D83C263B

Q27650860-26BA2D0E-AF44-4088-88B9-DC908BBDAAE4

Q27650860-4B276918-2BED-4E5B-9C54-06A110B374A4

Q27650860-8081FC92-6F96-4C0C-94EC-8068C5DC7FDF

Q27650860-84E28FFB-19CA-413E-8CC6-D4B6D1ED4414

Q27650860-C34F1C75-40B8-4BA3-BFF3-BBC301F16037

Q27650860-DAF3032C-38DC-4B7B-A8F9-65CFBBD352A9

P304

Q27650860-CB6C5475-3F6B-4CA6-8578-A7100237A8EB

P31

Q27650860-FD4AB1D2-E348-4719-A546-C30BC82EF396

P3181

Q27650860-B1C0F380-BE95-4AEB-920D-355EAD576C74

P356

Q27650860-172A1742-0005-4963-9E41-468B23F00A78

P407

Q27650860-DC7E949C-E097-45CD-A046-E232CDB23D76

P433

Q27650860-647D1753-6193-49B0-BD56-87474F4B9874

P478

Q27650860-ECDF17D8-77F8-401E-9121-BF770F453827

P50

Q27650860-E6F128A4-7069-4EA5-8807-4B239EC5BE97

P577

Q27650860-6A0C04E1-3C28-45C9-BFCA-03052D03ECD7

P698

Q27650860-C2889DA6-265A-46A6-9959-050B16242803

P3181

P356

0008-5472.CAN-07-6307

P1433

Cancer Research

P1476

BIBF 1120: triple angiokinase ...... de and good antitumor efficacy

@en

P2093

Andreas Zoephel

http://www.w3.org/2001/XMLSchema#string

Armin Heckel

http://www.w3.org/2001/XMLSchema#string

Frank Hilberg

http://www.w3.org/2001/XMLSchema#string

Gerald J Roth

http://www.w3.org/2001/XMLSchema#string

Gerd Bader

http://www.w3.org/2001/XMLSchema#string

Jens Quant

http://www.w3.org/2001/XMLSchema#string

Martin Krssak

http://www.w3.org/2001/XMLSchema#string

Susanna Kautschitsch

http://www.w3.org/2001/XMLSchema#string

Ulrike Tontsch-Grunt

http://www.w3.org/2001/XMLSchema#string

Wolfgang J Rettig

http://www.w3.org/2001/XMLSchema#string

P304

4774-82

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

332898

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-07-6307

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

68

http://www.w3.org/2001/XMLSchema#string

P50

Pilar Garin-Chesa

P577

2008-06-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18559524

http://www.w3.org/2001/XMLSchema#string